Literature DB >> 35213031

Preclinical Safety Assessment of Therapeutic Oligonucleotides.

Patrik Andersson1.   

Abstract

During the last decade, therapeutic oligonucleotide drugs (OND) have witnessed a tremendous development in chemistry and mechanistic understanding that have translated into successful clinical applications. Depending on the specific OND mechanism, chemistry, and design, the DMPK and toxicity properties can vary significantly between different OND classes and delivery approaches, the latter including lipid formulations or conjugation approaches to enhance productive OND uptake. At the same time, with the only difference between compounds being the nucleobase sequence, ONDs with same mechanism of action, chemistry, and design show relatively consistent behavior, allowing certain extrapolations between compounds within an OND class. This chapter provides a summary of the most common toxicities, the improved mechanistic understanding and the safety assessment activities performed for therapeutic oligonucleotides during the drug discovery and development process. Several of the considerations described for therapeutic applications should also be of value for the scientists mainly using oligonucleotides as research tools to explore various biological processes.
© 2022. The Author(s).

Entities:  

Keywords:  ASO; Antisense; Non-clinical safety assessment; Oligonucleotide drugs; Preclinical safety assessment; Toxicity; siRNA

Mesh:

Substances:

Year:  2022        PMID: 35213031     DOI: 10.1007/978-1-0716-2010-6_25

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  75 in total

Review 1.  Overview of alternative oligonucleotide chemistries for exon skipping.

Authors:  Amer F Saleh; Andrey A Arzumanov; Michael J Gait
Journal:  Methods Mol Biol       Date:  2012

Review 2.  The Medicinal Chemistry of Therapeutic Oligonucleotides.

Authors:  W Brad Wan; Punit P Seth
Journal:  J Med Chem       Date:  2016-07-29       Impact factor: 7.446

3.  Silencing of microRNAs in vivo with 'antagomirs'.

Authors:  Jan Krützfeldt; Nikolaus Rajewsky; Ravi Braich; Kallanthottathil G Rajeev; Thomas Tuschl; Muthiah Manoharan; Markus Stoffel
Journal:  Nature       Date:  2005-10-30       Impact factor: 49.962

Review 4.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

Review 5.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

Review 6.  RNA-Targeted Therapeutics.

Authors:  Stanley T Crooke; Joseph L Witztum; C Frank Bennett; Brenda F Baker
Journal:  Cell Metab       Date:  2018-04-03       Impact factor: 27.287

Review 7.  Therapeutic Antisense Oligonucleotides Are Coming of Age.

Authors:  C Frank Bennett
Journal:  Annu Rev Med       Date:  2019-01-27       Impact factor: 13.739

Review 8.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.

Authors:  Rajesha Rupaimoole; Frank J Slack
Journal:  Nat Rev Drug Discov       Date:  2017-02-17       Impact factor: 84.694

9.  Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy.

Authors:  Suzan M Hammond; Gareth Hazell; Fazel Shabanpoor; Amer F Saleh; Melissa Bowerman; James N Sleigh; Katharina E Meijboom; Haiyan Zhou; Francesco Muntoni; Kevin Talbot; Michael J Gait; Matthew J A Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-12       Impact factor: 11.205

Review 10.  The growth of siRNA-based therapeutics: Updated clinical studies.

Authors:  M May Zhang; Raman Bahal; Theodore P Rasmussen; José E Manautou; Xiao-Bo Zhong
Journal:  Biochem Pharmacol       Date:  2021-01-26       Impact factor: 6.100

View more
  1 in total

Review 1.  Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs.

Authors:  Damiano Bartolucci; Andrea Pession; Patrizia Hrelia; Roberto Tonelli
Journal:  Pharmaceutics       Date:  2022-07-12       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.